Investors & Media

Corporate Profile

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

Investor Relations

Sara Blum Sherman
Senior Director
Investor Relations & Strategy
+1 212-271-0740

Media Relations

Roberta Di Giorgio
Senior Director
Corporate Communications
+1 917-612-2861

to get the latest
DBV press releases

Press Releases


03/16/2018 - 9:30 pm | Corporate | Finance

DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

Download PDF (319 KB)

03/14/2018 - 2:30 am | Finance

DBV Technologies Reports Full Year 2017 Financial Results

Download PDF (398 KB)

03/07/2018 - 1:30 am | Conferences

DBV Technologies to Present at the Barclays Global Healthcare Conference

Download PDF (314 KB)


March 14, 2018

Barclays Global Healthcare Conference 2018

Go here for a live webcast of the presentation by DBV Technologies on March 14, 2018